1/29
Lecture 6
Is it common in clinics ? In general ? In our population ?
Will often see in clinic
Very common, increasingly rising in our population.
What is Alzheimers disease: Who discovered it ? When ? What is it ? (2) Prevalence ? Average survival from diagnosis ? Cure ?
Alois Alzheimer, 1907
Most common neurodegenerative disease
Progressive neurological disease which causes dementia
Prevalence increases with age– 7% of population between > 65 years– 15% of population > 75 years– 30% of population > 85 years
Average survival from diagnosis: 8-10 years
No cure
What are the stages of Alzeimers disease ?
Stage 1: no major impairment
Increased forgetfullness - also apparent in old age (they do not think they have a disease, more severe in stage 2.
Stage 2:
more severe memory loss, particularly for recent events
Storage of new memories imapired (short term memory is 1st affected)
errors in judgement / reasoning
Dysphagia / language difficulties
Restlessness (cannot sit still) / increased anxiety
Severe disorientation / confusion
Mood changes / depression / emotional instability
Psychosis / Hallucinations (later stage of stage 2)
Agression or docility
Stage 3:
All trace of presymtomatic personality lost
Mental emptiness
Loss of control of bodily functions
Severe debilitation, bed / wheelchair bound
Is Alzheimers a simple disease ? What does it affect ? (5)(5)(6)
Cognitive
Amnesia: memory formation
Aphasia - difficulty with language
Agnosia - difficulty identifying objects
Apraxia: problems with complex movements
Impaired executive functioning, reasoning (cannot have proper judgement and organising daily routines)
Behavioural
Depression
Agression
Apathy
Psychosis (some cases of this disease)
Psychomotor agitation
Functional
Social-Family Interaction
Independence
Maintaining hobbies
Driving
Handling Finances (need supervision)
Washing, Dressing, Eating
Alzeimers disease types: how many ? What are they called ? Which one is more common (%) ? What causes them ? What are they known as ?
~ 95 % is Late-OnsetAlzheimer’s disease, usually starts in 7-9th decade, of unknown cause sometimes termed “sporadic” Reason for this is not known.
~ 5% is Early OnsetAlzheimer’s disease can start at earlier age 4-5th decade due to inheritance of one faulty gene –in autosomal dominant fashion-termed “familial”
Alzeimers Disease Prevalence: How common is it ? What is _ ? Ageing ?
Alzheimers Disease is the most common dementia disorder
Dementia is a symptom, the main cause of which is AD
Dementia is NOT a normal part of ageing (impairement in cognition)
Dementia disorders ?
Alzheimers disease 60%
Vascular dementia (irregular blood supply of brain - causes memory impairement) 30%
Lew Body Dementia 10%
Frontotemporal Dementia 3%
Others - Picks Disease, Creutzfeldt - Jacob Disease, Parkinsons, Huntingtons (5%)
Prevalence of Dementia ? (3) Why is this happening ?
46.8 million - 2015
74.7 million - 2030
131.5 million - 2050
Prevalance of Dementia (3) ? Age ?
2015: 47.5 million cases of dementia worldwide
2011: approx. 48,000 individuals in Ireland have dementia
Prevalance of dementia increases exponentially with age
What happens in the AD brain location ? steps ? At what level ?
The changing brain in Alzheimers disease at a macroscopic level.
In the brains of people with Alzheimers disease:
The cerebral cortex degenerates damaging areas involved in thinking, planning + remmebering
Degeneration is especially severe in the hippocampus an area of the cortex that plays a key role in formation of new memories
Ventricles: (fluid-filled spaces within the body) grow larger
Understanding brain degeneration in Alzheimer’s Disease
Molecular neuropathology -Investigating the composition and biology of plaques and tangles
Where are tangles and plaques found and what do they cause ?
Tangles: found inside the neuron, leads to cell death
Plaques: found outside neurons, induce cell death.
Pathology features (3)
1. Deposition of β-amyloid (Aβ) protein around neurons: neuritic plaques (amyloid plaques - induce cell death)
2. Presence of intracellular accumulation of tau protein: form neurofibrillary tangles (accumulate as disease progresses + causes further damage.
3. Activation of microglia (immune cells, release cytokines + neurotransmitters cause chronic inflammation) and inflammation
Investigating plaques ? How does it form ? Part of what ? What happens ? Consistency ? (5)
Plaques form when small protein pieces called B-amyloid clump together - more severe as the disease progresses
B amyloid is part of a ,cuh larger protein callled amyloid precursor protein (APP)
B-amyloid is cut out of APP by the action of 2 enzymes: B and y secretase
B amyloid is chemically “sticky” and gradually sticks together to form insoluable plaques at synapses + around nerves
mutations in these enzymes - accumulation of these amyloid plaques leads in the end to formation of these plaques.
Investigating tangles: What are they ? In healthy neruons ? In Alzeimers ? Eventually what will happen ?
Tangles are clumps of tau protein inside neurons
In healthy neruons, tau binds to and helps microtubles in axons, which are vital for neuron structure and function
In alzheimers, tau comes of the micritubles, moves into soma and dendrites - gains aberrant functions + sticks to itself forming paired filaments + insoluble clumps
Microtubule units in axons fall apart and distintegrate
Neurons with tangles eventually die
Stages in AD ? Linking ?
Stages of AD
Plaques + Tangles linked to disease symptoms
Stage 1: not much symptoms, memory impairement, hippocampus
Plaques and tangles appear in areas associated with memory, learning, thinking and planning
changes may begin 10 years or more before diagnosis
Stage 2:
Plaques and tangles spread to areas associated with speech, understanding, orientation (hippocampus - temporal area)
Generally lasts from 2-10 years
Stage 3: spread into main area of cortex + frontal cortex
Plaques and tangles are widespread in the cortex
Patients usually restricted to bed. Cannot form memories, orientation problems, need help eating, washing, dressing
Severe neuron loss occurs
May last from 1 to 5 years
What are we looking at now ?
Neurochemical approach –investigating whether Alzheimer’s is due to loss of selective neurotransmitter systems
What happens neurotransmitter systems in AD ?
There is changes
Neurotransmitter systems in Alzheimers disease (4)
1976-80s - selective loss of markers of acetylcholine (most common system) were identified in Alzheimer’s disease
1980s to present day - drug treatments for Alzheimer’s disease were developed to stop acetylcholine being degraded
1980s to present day –realisation that acetylcholine is not the only neurotransmitter system affected in Alzheimer’s disease
Several neurotransmitter systems are affected including glutamate ( affects the excitatory neurotransmission), serotonin, noradrenaline
What was believed in former times and how was this proves wrong ?
Neurons in the hippocampus and cerebral cortex that produce acetlycholine degenerate:
Loss of cholinergic function correlates with cognitive and memory deficits
But system is outdates as we know that acetylcholine + other neurotransmitter systems are affected.
relationship ?
The relationship between: • Neuritic plaques • Neurofibrillary tangles • Cholinergic degeneration is not known
What are we looking at now ?
Molecular genetics– Identifying the genes that: cause the familial (inherited) forms of Alzheimer’s disease are linked to the idiopathic forms of Alzheimer’s disease
Molecular genetics of AD ?
1991 – Mutations in the APP geneon chromosome 21 discovered to cause familial Alzheimer’s Disease: 1% of all familial Alzheimer’s cases & Down’s syndrome, trisomy 21, develop early onset AD (40’s), 75% of over 60 years DS have AD
1995 - Mutations in Presenilin 1(PS 1) gene on chromosome 14 discovered to cause most cases of familial Alzheimer’s disease & 50-60% of all familial Alzheimer’s cases
1998 - Mutations in taugene on chromosome 17 discovered to cause a dementia disorder (not Alzheimer’s disease)
1993 – ApolipoproteinE(ApoE) e4 allele identified as a susceptibility risk gene for non-familial “sporadic” forms of Alzheimer’s
Research continues in these families
Diagnosis: (6) No what ?
Medical history
We have no biomarkers to diagnose
Interviews with family members: often patients ate so severely cognotively impaired
Memory tests: Mini-mental state exam MOCA (montreal cognitive Ax ) (spatial memory, long term memory, short term memory)
Absence of other neurological symptoms
Brain imaging: Magnetic reasonance imaging (MRI)
Computed tomography (CT) visualise plaques (only possible @ end stage)
Only certan at post-mortem
Treatment ?
No existing drugs to cue AD or stop progression
Currently used therapies to alleviate symptoms
Cholinesterase inhibitors (increase amount of acetylcholine in synaptic cleft, Often given to patients in former times not very effective does not help memory)
Donepezil (Aricept) approved for all stages
Rivastigmine (Exelon) All stages
Galantamine (Reminyl, Galysa SR) mild - moderate
Glutamate receptor antagonist
Memantine (Namenda) moderate - severe, does not restore full effect of memory
AD drug treatment: (4)
Acetylcholinesterase inhibitors– increases the synthesis of acetylcholine
Acetylcholine → → Choline + acetic acid , because of the enzyme Acetylcholinesterase
• Memantine– blocks the effect of high levels of glutamate
• Drugs for psychiatric and behavioural symptoms– Neuroleptics– Antidepressants
• (Other) – (Antioxidants e.g.. vitamin E)
Non drug treatment for AD ? (6)
OT
SLT
Assitive technology (walking aids, wheelchairs, prevent risk of falls)
Social support
Psychological therapies
Family support
what causes Alzheimers disease ? Risk factors (5) Modified risk factors (2) Lifetsyle (4) ? What has an important input on AD ?
For most patients, the cause of Alzheimer’s disease is unknown
Risk Factors
Age
Head trauma
Inflammation
Oxidative Stress
Susceptibility genes e.g. ApoE, APP, Presenilin
Modifiable Risk Factors
Cardiovascular /metabolic:
Mid-life hypertension / hypercholesterolemia / cardiovascular disease
Diabetes
Lifestyle:
Lack of exercise
Stress
Diet
Years of education
Prospects (3)
Earlier diagnosis
More effective therapies
Shift age of onset to the right